These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 11255888)

  • 1. [Acute hemodynamic and clinical effects of a new inotropic agent, levosimendan, in patients with severe heart failure].
    Porcu M; Orrù P
    Ital Heart J Suppl; 2001 Feb; 2(2):205-6. PubMed ID: 11255888
    [No Abstract]   [Full Text] [Related]  

  • 2. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan: a new approach for the treatment of patients with severe heart failure. A brief summary based on a clinical case.
    Morais J; Dias B; Pontes N
    Rev Port Cardiol; 2003; 22(7-8):941-8. PubMed ID: 14587161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
    Follath F; Franco F; Cardoso JS
    Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: a new option in acute septic cardiac failure?
    Powell BP; De Keulenaer B
    Emerg Med Australas; 2007 Apr; 19(2):177; author reply 177-8. PubMed ID: 17448109
    [No Abstract]   [Full Text] [Related]  

  • 7. A promising new inotrope: levosimendan.
    Fotbolcu H; Duman D
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
    Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 12. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of levosimendan in acute heart failure and its effect on renal function].
    Moyano AP; Hidalgo RL; Grande DB; Morales SC
    Nefrologia; 2009; 29(6):616-7. PubMed ID: 19936016
    [No Abstract]   [Full Text] [Related]  

  • 15. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
    Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
    Int J Cardiol; 2010 Feb; 138(3):281-9. PubMed ID: 18817994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan.
    Kamath SR; Jaykumar I; Matha S
    Indian Pediatr; 2009 Jul; 46(7):593-6. PubMed ID: 19638658
    [No Abstract]   [Full Text] [Related]  

  • 17. Levosimendan: The current situation and new prospects.
    Moreno N; Tavares-Silva M; Lourenço AP; Oliveira-Pinto J; Henriques-Coelho T; Leite-Moreira AF
    Rev Port Cardiol; 2014 Dec; 33(12):795-800. PubMed ID: 25459636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
    Yontar OC; Yilmaz MB; Yalta K; Tandoğan I
    Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan: implications for clinicians.
    McBride BF; White CM
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.